Tarsus Pharmaceuticals, Inc.(TARS)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

Tarsus Pharmaceuticals, Inc. (TARS) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores TARS at 55.0/100 on a 32-signal composite quality model, placing it at rank #1,280 of 2,962 stocks — the top half of the AI-ranked universe. TARS scores in the top quartile across revenue growth (98.5), earnings quality (76.9). Areas of concern include balance sheet strength (18.7) and profitability (29.6), which score below median versus the broader universe. Shareholder dilution risk is elevated at 17.1/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Tarsus Pharmaceuticals, Inc. reports quarterly revenue of $173.9M, net income of $-18.6M, an operating margin of -11.5%. Top institutional holders of TARS by reported 13-F value include BlackRock, Deep Track Capital, RTW INVESTMENTS, based on the most recent SEC filings. TARS trades on the Nasdaq exchange and files with the SEC under CIK 1819790. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate TARS daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Tarsus Pharmaceuticals, Inc. directly from SEC EDGAR.